IFNA1 and cancer: Hiltonol® has been studied in clinical trials as a cancer therapy and as an adjuvant for cancer vaccines.9 Poly I:Poly C12U (rintatolimod, Ampligen®) (Hemispherx Biopharma, Inc., Philadelphia, PA, USA) was designed as an IFN inducer with a markedly reduced incidence of adverse advents compared to the parent compound Poly I:Poly C8 and is devoid of adducts.